Lipid-Polymer Hybrid Nanoparticles for Controlled Delivery of Hydrophilic and Lipophilic Doxorubicin for Breast Cancer Therapy by Tahir, Nayab et al.
OR I G I N A L R E S E A R C H
Lipid-polymer hybrid nanoparticles for controlled
delivery of hydrophilic and lipophilic doxorubicin
for breast cancer therapy
This article was published in the following Dove Press journal:
International Journal of Nanomedicine
Nayab Tahir1–3
Asadullah Madni2
Alexandra Correia3
Mubashar Rehman4
Vimalkumar Balasubramanian3
Muhammad Muzamil Khan2
Hélder A Santos3,5
1College of Pharmacy, University of
Sargodha, Sargodha, Pakistan; 2Department
of Pharmacy, The Islamia University of
Bahawalpur, Bahawalpur 63100, Pakistan;
3Drug Research Program, Division of
Pharmaceutical Chemistry and Technology,
Faculty of Pharmacy, University of Helsinki,
Helsinki FI-00014, Finland; 4Department of
Pharmacy, The University of central Pujnab,
Lahore, Pakistan; 5Helsinki Institute of Life
Science (HiLIFE), University of Helsinki,
Helsinki FI-00014, Finland
Background: Lipid polymer hybrid nanoparticles (LPHNPs) for the controlled delivery of
hydrophilic doxorubicin hydrochloride (DOX.HCl) and lipophilic DOX base have been fabri-
cated by the single step modiﬁed nanoprecipitation method.
Materials and methods: Poly (D, L-lactide-co-glicolide) (PLGA), lecithin, and 1,2-dis-
tearoyl-Sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)-2000 (DSPE-
PEG 2000) were selected as structural components.
Results: The mean particle size was 173–208 nm, with an encapsulation efﬁciency of 17.8
±1.9 to 43.8±4.4% and 40.3±0.6 to 59. 8±1.4% for DOX.HCl and DOX base, respectively.
The drug release proﬁle was in the range 33–57% in 24 hours and followed the Higuchi
model (R2=0.9867–0.9450) and Fickian diffusion (n<0.5). However, the release of DOX base
was slower than DOX.HCl. The in vitro cytotoxicity studies and confocal imaging showed
safety, good biocompatibility, and a higher degree of particle internalization. The higher
internalization of DOX base was attributed to higher permeability of lipophilic component
and better hydrophobic interaction of particles with cell membranes. Compared to the free
DOX, the DOX.HCl and DOX base loaded LPHNPs showed higher antiproliferation effects
in MDA-MB231 and PC3 cells.
Conclusion: Therefore, LPHNPs have provided a potential drug delivery strategy for safe,
controlled delivery of both hydrophilic and lipophilic form of DOX in cancer cells.
Keywords: lipid polymer hybrid, doxorubicin, breast cancer, nanotechnology, drug delivery
Introduction
Cancer is ranked among the most highly prevalent diseases and is the second
leading cause of mortality and morbidity globally.1 According to the World
Health Organization (WHO), prostate cancer is listed as the most commonly
occurring cancer among males (ca. 25% of all the newly diagnosed patients) and
breast cancer among females (more than 25% of total cases).2 Use of different
chemotherapeutic agents has been employed as the most efﬁcient approach for
the treatment of the cancer. Currently, doxorubicin (DOX), etoposide, docetaxel,
and cisplatin are considered most effective chemotherapeutic agents.3 However,
the delivery of these chemotherapeutic agents might be associated with multi-
faceted challenges, such as a lack of speciﬁcity to retain the therapeutic agent in
the cancer environment, low solubility in the aqueous media, rapid elimination,
and non-speciﬁc distribution, demanding larger dose administration, which leads
to dose-related toxicities.4,5
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Nanotechnology presents an advanced platform for the
treatment of cancer by developing novel nanocarriers sys-
tems for the administration of chemotherapeutic agents, ran-
ging from the small hydrophilic and lyophilic molecules to
large peptides and proteins.6 In the last few decades, various
nano-sized drug delivery systems (DDS) have been designed,
fabricated, and approved for clinical use, while a large num-
ber of DDS are still under clinical trials for the diagnostic and
therapeutic applications.7 Polymeric DDS and lipid based
nanocarriers have been listed as the most important systems.
Liposomal carriers offer advantages in terms of better com-
patibility, superior pharmacokinetic characteristics, longer
retention time, and easy surface modulation. Moreover, the
polymeric carriers offer prolonged and controlled drug
release from the system and excellent stability proﬁles.
Despite all of these properties, both liposomes and polymeric
carrier systems have limitations in terms of drug stability,
drug leakage, low loading capacity, and compatibility.8
Recently, the integration of these systems (liposomes
and polymeric nanoparticles, NPs) provide a novel
domain of DDS, termed as the lipid polymer hybrid
nanoparticles (LPHNPs), that hold promising applica-
tions in the diagnostic imaging and treatment of different
carcinomas, as shown in Figure 1.9 In contrast to other
carriers, the LPHNPs offer some unique features, includ-
ing the diversity in structural components, higher encap-
sulation, controlled drug release, biocompatibility,
improved stability proﬁle, enhanced permeability, and
cellular uptake.10,11 These particles also have the capa-
city to encapsulate the hydrophilic and hydrophobic ther-
apeutic moieties.
DOX is an antineoplastic agent of non-selective class
I anthracycline antibiotics class that are regarded as the
most effective anticancer drugs.12 It has been clinically
employed alone or in combination for treating various
carcinomas.13 Despite of its potential beneﬁts, DOX also
have dose dependent cardiac toxicities, such as congestive
heart failure and chronic cardiomyopathy.14 Different stu-
dies have reported superior efﬁcacy of nano-encapsulated
hydrophilic DOX.HCl and lipophilic DOX. However, lim-
ited studies were performed previously to study the differ-
ence in the chemical form and the hydrophobicity on the
antitumor activity of DOX.
In this study, we developed DOX.HCl and DOX base
encapsulated LPHNPs by using the self-assembling mod-
iﬁed nanoprecipitation method. The main aim of the study
was to compare the physicochemical and therapeutic prop-
erties of the DOX.HCl and DOX base that provide the
sightful information about the co loading of hydrophilic
and lipophilic drugs in the LPHNPs for better drug ther-
apy. Poly (D, L-lactide-co-glicolide) (PLGA) was
employed as an inner core material, owing to its biode-
gradable and biocompatible nature. Likewise, the mixture
of lecithin and 1,2-distearoyl-Sn-glycero-3-phosphoetha-
nolamine-N-[methoxy (polyethylene glycol)-2000 (DSPE-
PEG 2000) was used as lipid. LPHNPs were characterized
for various physicochemical, compatibility, and solid state
properties. In addition to physicochemical characteriza-
tion, the DOX.HCl and DOX-base-loaded LPHNPs were
fabricated with different drug-to-polymer ratios compared
to the drug loading, entrapment, and drug release behavior.
The in vitro cytotoxicity, antiproliferative activity, and cell
uptake studies were performed to simulate the in vivo fate
and activity of these LPHNPs in various cancerous cells to
determine any difference in the activity of DOX.HCl and
DOX base loaded in the LPHNPs.
Materials and methods
Materials
DOX was procured from Tokyo Chemical Industry Co.
Ltd, Japan. PLGA, 50:50 was obtained as a kind gift from
Purac Biomaterials (Netherlands). Lecithin (98%) was
acquired from Sigma Aldrich (St. Louis, MO, USA).
DSPE-PEG 2000 was procured as research sample from
the Lipoid GmbH (Ludwigshafen, Germany). Hank’s bal-
ance salt solution (HBSS), trypsin (2.5%), Dulbecco’s
Modiﬁed Eagle Medium (DMEM), phosphate buffered
saline (PBS), Rosewell Park Memorial Institute (RPMI),
L-glutamine (200 mM), fetal bovine serum (FBS, 10%),
non-essential amino acids (NEAA), and penicillin-
streptomycin (PEST) were all procured from HyClone
(USA). American Type Culture Collection provided all
the required cell lines used in the present study. Freshly
prepared Milli-Q water (Merck Millipore, USA) was used
PLGA Doxo
Self
assembly
LPHNPs
Lipid
phase
Aqueous
phase
Lecithin
DSPE-PEG-2000
Figure 1 Schematic diagram of the LPHNPs.
Abbreviations: Doxo, Doxorubicin; DSPE-PEG 2000, 1,2-distearoyl-Sn-glycero-3-
phosphoethanolamine-N-[methoxy (polyethylene glycol)]-2000; LPHNPs, lipid poly-
mer hybrid nanoparticles; PLGA, poly (D, L-lactide-co-glicolide).
Tahir et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
International Journal of Nanomedicine 2019:144962
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
21
4.
91
.1
33
 o
n 
12
-A
ug
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
in the preparation of formulation and buffers. All the
other necessary chemicals and reagents used in the
study were of analytical grade, and all solvents were of
HPLC grade.
Preparation of doxorubicin base
Before the preparation of the LPHNPs, the DOX.HCl was
converted into the hydrophobic base by extraction method.
Brieﬂy, a calculated amount of the DOX.HCl was dissolved
in 5 mL of the Milli-Q water with continuous stirring;
01 mL of 0.2 M of sodium bicarbonate was added and
mixed thoroughly for 5 minutes. The mixture was transfer
into a separating funnel followed by the addition of chloro-
form. The chloroform layer was collected and the process
repeated twice. Lastly, the organic solution was evaporated
by rotary evaporator to get the DOX base.
Fabrication of the LPHNPs
NP formulations were produced by modiﬁed single step nano-
precipitation process, using the DOX.HCl, DOX base, PLGA,
lecithin, and DSPE-PEG 2000 as structural components.
Brieﬂy, the organic phase containing polymer was prepared
with a speciﬁc concentration (2 mg/mL) in acetonitrile. While
the solution of lecithin and DSPE-PEG 2000 in a mass ratio of
2:3 in 4% of hydroethanolic solution constitute the aqueous
phase. The amount of added lipid was 20% of the total weight
of the PLGA used in the organic phase. The aqueous phase
was heated at 65°C so that all the lipids melt and properly
disperse in the hydroethanolic solution constituting the uni-
form aqueous phase. The ﬁnal dispersion was prepared by the
addition of organic phase in dropwise manner in the hydro-
ethanolic solution in a 1:9 v/v ratio, by using the syringe pump
under gentle stirring. Finally, the LPHNPs were puriﬁed and
washed twice with Milli-Q water by centrifugation to remove
the unentrapped drug and organic solvents. The above-
mentioned procedure was also applied to fabricate the drug
loaded LPHNPs. The speciﬁc amount of the DOX.HCl was
added into the hydroethanolic phase, whereas the DOX base
was dissolved into the organic solvent.
Characterization of the LPHNPs
Morphology
Transmission electron microscope imaging was employed to
evaluate the shape and surface morphology of the fabricated
LPHNPs. TEM analysis was performed by depositing the
sample particles on the 400 mesh carbon coated copper grids
using the negative staining approach.15 Brieﬂy, the
dispersion of the LPHNPS was deposited on the TEM grid
by placing the drop of sample NPs for speciﬁc time interval.
Finally the grid was stained with negative stain (2% uranyl
acetate), dried, and then visualized at a voltage of 120 kV by
using TEM (Jeol JEM-1400, Jeol Ltd, Tokyo, Japan).16
Particle size, zeta-potential, and size distribution
analysis
Malvern ZetaSizer Nano ZS instrument (Malvern
Instruments Ltd, Malvern, UK) was employed to evaluate
the mean particle size, particle size distribution, and zeta-
potential of prepared nanoformulations. The dynamic
light scattering (DLS) method indicates the z-average
and polydispersity (PDI) of NPs in blank and drug loaded
LPHNP formulations. The zeta-potential analysis used an
electrophoretic mobility approach.17
Encapsulation efﬁciency
The direct measurement of the ﬂuorescence of DOX in the
sample was utilized for the calculation of the amount of
drug encapsulated in all LPHNP formulations at 480 nm to
560 nm as excitation and emission wavelengths, respec-
tively, because of the ﬂorescent nature of the DOX using
the ﬂuorescent detector (Thermo Fisher Scientiﬁc Inc.,
Waltham, MA, USA). The indirect method was employed
using the supernatant to calculate the unentrapped DOX in
the formulation. Finally, the amount of the encapsulated
DOX was determined by using the following formula.
%E:E ¼ Amount of DOX loaded in LPHNPs
Total amount of DOX added in formulation
 100
(1)
Drug release and kinetics
The membrane dialysis approach was used to evaluate
the in vitro drug release from LPHNPs that simulate the
ultimate performance of the DDS in the biological
ﬂuids. Brieﬂy, an accurately calculated amount of NPs
which encapsulated a ﬁxed amount of DOX.HCl and
DOX base were dispersed in the 1 mL of dissolution
media (PBS pH 7.4), and this was put into the respective
dialysis bags with 10–12 kDa average cutoff molecular
weight. The dialysis bags were sealed with clips and
placed in 40 mL of dissolution medium to study the
release of the DOX for 24 hours The dialysis bags
were placed on a magnetic stirrer at controlled tempera-
ture with a gentle shaking rate of 150 rpm. Then 200 µL
of the sample was withdrawn and added in the 96-well
plates at different predetermined time intervals (0, 0.25,
Dovepress Tahir et al
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0.5, 0.75, 1, 2, 3, 4, 5, 6, 8, and 24 hours) in triplicate
manner. After each sample, the same amount of the
fresh dissolution medium maintained at the same tem-
perature was added to keep the amount of dissolution
medium constant throughout the experiment. The
amount of the DOX released from the LPHNPs was
determined by calculating the total ﬂuorescence of the
drug in the sample by Varioskan Plate reader at 480 nm
and 560 nm as excitation and emission wavelengths,
respectively.
The kinetics analysis of the DOX released from the
LPHNPs was determined by incorporating the resultant
data into various mathematical models. The regression
coefﬁcients (R2) values will indicate the best ﬁt model.
Fourier transform infrared (FTIR) spectroscopy
The interaction among the drug and the formulation com-
ponents is signiﬁcantly important to determine the efﬁcacy
and stability of the formulation. Solid state analysis was
employed to determine the compatibility among the various
components used in the present study. First, FTIR spectra of
all the pure ingredients, drug, their physical mixtures, blank,
and DOX loaded NPs were recorded by using FTIR and
analysis for the characteristic peaks and their shift in indi-
vidual to formulation spectra using OPUS 5.5 software. All
the spectra were recorded from 3,500 to 500 cm−1 wave-
length, with 4 cm−1 resolution and 64 scans.
Differential scanning calorimetry (DSC)
All the individual ingredients, their physical mixture, and
the LPHNPs were analyzed by DSC to identify the solid
state of the entrapped drug within the NPs. The DSC
thermograms were recorded using the calorimeter that is
previously standardized for the temperature and rate of
heat ﬂow by using Indium (melting point=157.6°C) as
reference standard throughout the experiment (DSC 823e,
Mettler Toledo, USA). Brieﬂy, the accurately weighed
samples were packed in the aluminum pans. Then the
samples were analyzed by heating the samples from 25
to 250°C at 10°C/min linear heating rate with constant
ﬂow of the nitrogen that create an inert environment. The
measured data was evaluated by STARe software.
Colloidal stability of LPHNPs
To evaluate the possible in vivo behavior, the stability of
the prepared nanoparticles was determined in FBS, RPMI,
and DMEM;100 mg of the powdered NPs were dispersed
in the 2 mL of the respective solution and keep at 37°C
under constant stirring of 100 rpm; 200 μL of each sample
was collected at constant periods of time intervals and
analyzed by using the Zetasizer Nano ZSP (Malvern
Instruments) for any change in the particle size, polydis-
persity, and zeta-potential. All the data was collected from
three independent experiments and expressed graphically.
Cell culturing
The various cancer cells (breast and prostate cancer) were
grown separately in DMEM and RPMI culture media at
37°C, and 95% humidity with 5% CO2 in a gas incubator
(BB 16 gas incubator, Heraeus Instruments GmbH). Both
the cell culture media were supplemented with 10% FBS,
1% NEAA, and 1% PEST. Before every test, the cells
were unthaw, subcultured at 80% conﬂuency, and seeded
for further experiments.
In vitro cytotoxicity studies
The viability assay of all the selected LPHNPs was per-
formed to access the in vitro cytotoxicity and nanoformu-
lations. The ATPase activity based viability kits were used
to measure the viable cells.18 Brieﬂy, the cells were grown
and seeded by using the aforementioned protocol.
An accurately weighed amount of the NPs were dispersed
in the growth media to prepare all the samples, with
concentrations ranging from 50–300 µg/mL. Cells were
grown for proper attachment to the wall of the plate.
Later, the cells were washed with the buffer and incubated
with all the samples for the required period of time in 96-
well plates. After incubation, the plates were equilibrated
for 30 minutes at ambient temperature. Finally, the cells
were washed with HBSS-HEPES buffer and treated with
50 µL CellTiter-Glo® (Luminescent Cell Viability Assay,
Promega Corporation, USA) and 50 µL buffer in each
well. The reagent was mixed properly with the cells by
placing the plate on the orbit shaker for 2 minutes. The
samples were placed in the Varioskan plate reader (Thermo
Fisher Scientiﬁc Inc.) to measure the luminescence, which
is directly correlated with the number of viable cells in the
samples. All the results were taken as three independent
readings and compared with negative and positive
controls.
Cell uptake study
Cell internalization analysis is a valuable index to measure the
ability of drug to enter in the cell and the concentration inside
the cells. For the qualitative analysis of the cell internalization,
human prostate and breast cancer cells were seeded and grown
into a Lab-tek™ 8-chambered glass plate. Then 200 µL of the
cells were added in each chamber and grown overnight for the
Tahir et al Dovepress
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proper attachment with the chamber.19 The cells were washed,
treated with the 200 µL of DOX.HCl and DOX base loaded
LPHNPs suspension, and incubated under the aforementioned
growth conditions. Cells incubated without the NPs in the
medium were considered as negative controls. Finally, the
cells incubated with the samples were washed and stained by
the following protocol. Brieﬂy, the staining of cell membranes
and nuclei was achieved by incubating the cells with 200 µL of
DAPI (Thermo Fisher Scientiﬁc) and CellMask Deep Red
(Life Technologies, US) for 5 and 3 minutes at 37°C, respec-
tively. The excess of staining reagent was removed bywashing
and all the cells were ﬁxed with 4% paraformaldehyde (PFA)
for 15 minutes. The ﬁxed cells in fresh buffer (pH 7.4) were
analyzed by using a Leica inverted SP5 confocal microscope
usingHeNe (590 nm), Ar (488 nm), andHeNe (633 nm) lasers
for the intracellular internalization of the LPHNPs and the drug
molecules.
Antiproliferative assay
The antiproliferative action of pure drug solution, DOX.
HCl, and DOX base loaded LPHNPs were determined by
the cell proliferation experiments against the breast and
prostate cancer cells. Brieﬂy, all the cell were grown in
accordance with the previously mentioned cell culturing
protocol and incubated for attachment for 24 hours at
a speciﬁc temperature. After incubation and attachment,
the cells were washed and grown with the free drug solu-
tion, and the drug loaded LPHNPs suspension with differ-
ent concentrations (ranging from 5 µg/mL to 200 µg/mL
for all the three type of formulations) and incubated for the
preselected time intervals. The live cell count was deter-
mined by using the viability assay kit (CellTiter-Glo®,
Promega Corporation, USA) and the sample plates were
analyzed for the luminescence in a Varioskan lumines-
cence plate reader.
Statistical analysis
All the experimental data of the present study was pre-
sented as the result ± standard deviation. All the test
results were taken in triplicate under same experimental
conditions. The signiﬁcance of different results was calcu-
lated by using the ANOVA.
Results and discussion
Morphology
TEM images of DOX.HCl andDOX base loaded LPHNPs are
shown in Figure 2. All the formulations showed round, smooth
surfaced, and nanosized particles. The inner bright portion of
the NPs might indicate the presence of polymeric core encap-
sulating the drug. It is also evident that the drug loaded NPs
maintained the uniform shape and surface with a slight
increase in the size of the particles in agreement with previous
studies. The TEM images of the blank LPHNPs (Figure 2C
andD) indicate that there is no such bright cores are the present
in the lipid coating that support the abovementioned results.20
Particles size, size distribution, and
zeta-potential
The DLS method was employed to determine the size of the
NPs. The blank LPHNPs were of 173.9±2.4 nm, which was
slightly less than the particle size of drug loaded LPHNPs
(182–208 nm) with a value of monodispersity (less the 0.16),
as presented in Table 1. It was observed that the LPHNPs
loaded with DOX base were relatively smaller (up to 185 nm)
in size as compared to DOX.HCl loaded nanoparticles (up to
208 nm) (Table 1). The results suggest that there are smaller
NPs formed with an increase in the hydrophobicity of the
chemical constituents that might develop a better electrostatic
and steric repulsion between the LPHNPs.21 This size range
is desirable for prolonged circulation and enhanced cell
500  nm
500 nm
A B
D E F
C
2   µm
2   µm
500  nm
500  nm
Figure 2 TEM images of DOX.HCl (A and B), Blank LPHNPs (C and D), and DOX base (E and F) loaded LPHNPs.
Abbreviations: DOX, doxorubicin; DOX.HCl, doxorubicin hydrochloride; LPHNPs, lipid polymer hybrid nanoparticles; TEM, transmission electron microscopy.
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uptake.22 All the formulations showed negative zeta-potential
(−31.7 to −28.0 mV) due to the presence of negatively charge
lecithin, and their lipophilic properties in the NP matrix. This
range of zeta-potential provides adequate repulsion between
NPs and prevents aggregation in the liquid media, leading to
good colloidal stability, as suggested by the previously pub-
lished data.23
Encapsulation efﬁciency
The encapsulation efﬁciency (%EE) of DOX.HCl and DOX
base loaded LPHNPs was measured by a direct method.
From the data presented in Table 2, it is evident that the
encapsulation is directly proportional to the amount of the
polymer as compared to drug. Interestingly, the EE of the
DOX base was higher as compared to the DOX.HCl at the
constant amount of drug and polymer. The increased hydro-
phobicity of the drug proportional to EE and drug might be
the reason for the increase in the overall entrapment efﬁ-
ciency of the system. It was also supported by the previous
studies that the solubility in the aqueous medium and their
interaction with the lipid component of the formulation. The
Hydrophobic drug easily partitioned between the lipid layers
as compared to the hydrophilic DOX.HCl that lead to
a higher encapsulation of the hydrophobic drug as compared
to the hydrophilic DOX.HCl.24,25
Drug release and kinetics
The in vitro drug release studies were performed using
a dialysis bag method in PBS (pH 7.4) dissolution medium.
The amount of drug released from theNPs is shown in Table 3.
All formulations showed a biphasic drug release pattern.
However, the release of DOX.HCl was relatively faster than
DOX base. Lesser aqueous solubility and high association
with the lipid components might contribute to controlled
release of DOX base from the prepared LPHNPs.26,27 The
better solubility of the DOX.HCl in the aqueous media lead to
rapid diffusion of the drug molecules from the LPHNPs, as
compared to the DOX base loaded formulations. Moreover,
due to the hydrophobic nature of the lipid, the aqueous media
access is limited towards the nanoparticles. In addition to that,
the DOX base is a highly hydrophobic one, which
releases from the formulation very slowly in the given period
of release studies. In the kinetic analysis, the values of the
correlation coefﬁcient and diffusional coefﬁcient (n) (Table 3),
indicating that all the NPs containing DOX.HCl and DOX
base follow the Fickian diffusion (n<0.5) mechanism
of release from the LPHNPs with the Higuchi
(R2=0.9867–0.9450) kinetic model.28,29
Fourier transform infrared (FTIR) study
Previously, we conducted a comprehensive study to evaluate
the compatibility and presence of any possible physical and/
or chemical incompatibility between the different structural
components of DDS.30 In this study, the characteristic FTIR
spectra of all pure chemicals, blank and DOX loaded
LPHNPs were also recorded, as shown in Figure 3. The
FTIR spectra of DOX in Figure 3D indicates the character-
istic bands at 3,320 cm−1 (N-H asymmetric stretching), and
2,935 cm−1 (C-H stretching vibration). The band at 1,730
cm−1 shows the presence of the C-O group,31 whereas dis-
tinct bands at 1,615 cm−1 and 1,580 cm−1 correspond to the
bending vibration of amide I and amide II groups, respec-
tively, that overlap with the carbonyl groups of the anthra-
cene ring.32,33 The IR spectra of PLGA (Figure 3A) indicate
the characteristic bands at 2,995 cm−1 and 2,946 cm−1, spe-
cifying the -C-H symmetrical stretching at C-H and methyl
(CH)3 group associated with the lactic acid monomer of
PLGA, while distinct bands located at 1,452 and 1,423 cm−1
indicate the occurrence of a glycolic acid fraction of the
polymer.34 The sharp band at 1,747 cm−1 corresponds to
Table 1 Size, polydispersity (PDI) and zeta-potential of different
prepared formulations
Sample
code
Particle size
(nm)
PDI Zeta-potential
(mV)
FH1 204.8±1.4 0.050±0.007 −31.7±1.2
FH2 207.5±1.0 0.089±0.021 −29.8±0.8
FH3 201.4±3.1 0.085±0.031 −28.8±0.6
FB1 182.4±1.0 0.183±0.037 −32.5±0.6
FB2 183.8±0.8 0.153±0.015 −32.0±0.9
FB3 185.8±3.2 0.154±0.240 −29.6±1.7
FBlank 173.9±2.4 0.069±0.016 −28.0±0.1
Table 2 Entrapment efﬁciency (EE) and percentage of drug
release of the different prepared formulations
Sample
code*
Drug/poly-
mer ratio
Entrapment
efﬁciency
% Drug
release
*FH1 1:5 17.80±1.91 53.23
*FH2 1:10 30.11±1.17 56.72
*FH3 1:20 43.80±4.36 48.76
**FB1 1:5 40.32±0.60 33.29
**FB2 1:10 52.87±0.34 35.57
**FB3 1:20 59.78±1.35 32.93
Note: *Formulations FH1–FH3 were LPHNPs loaded with DOX.HCl, while **FB1
–FB3 were loaded with DOX base.
Abbreviations: DOX, doxorubicin; DOX.HCl, doxorubicin hydrochloride; LPHNPs,
lipid polymer hybrid nanoparticles.
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the ester carbonyl group symmetric stretching (-C=O).35 The
spectra of the physical mixture demonstrate the characteristic
bands of all the individual components without any remark-
able shift from the normal position. The FTIR spectra of
blank LPHNPs (Figure 3E) indicate the presence of distinct
bands of the PLGA and lecithin, which is supported by the
data in different studies.36,37 The data suggest that there was
no signiﬁcant shift in the pattern of peaks of the polymer and
lipid in the FTIR spectra of blank LPHNPs that strengthen
the lack of any possible physical and chemical interactions
with the loaded drug molecules. The slight shift of distinct
bands of DOX at 3,268 cm−1 and 3,270 cm−1, demonstrating
N-H stretching of drug in the prepared formulations, was not
observed in the IR spectra of blank LPHNPs (Figure 3F).
However, intense signals of the carbonyl (C=O) group show
a slight shift in wave number at 1,753 cm−1, which might be
due to the overlapping of identical groups in lecithin and
PLGA.38
Differential scanning calorimetry (DSC)
analysis
Thermal analysis was performed to determine any possi-
ble change in physical characteristics of the formulation
components individually and to evaluate crystalline or
amorphous behavior of the DOX loaded in the
LPHNPs. The phase transition studies might indicate
the changes in the crystallinity of the drug that affect
the in vitro drug discharge process and in vivo cellular
Table 3 Kinetic modeling of drug release of different prepared formulations after data ﬁtting in different kinetic models
Formulations Zero order First order Higuchi model Korsmeyer-Peppas model
R2 Ko R
2 K R2 KH R
2 N
*FH1 0.8997 4.0231 0.8039 0.0596 0.9867 23.8213 0.9891 0.4366
*FH2 0.7922 2.9944 0.6979 0.0685 0.9542 25.9411 0.9485 0.4061
*FH3 0.7529 1.8092 0.6825 0.0443 0.9366 24.3306 0.9416 0.3388
**FB1 0.8705 2.2866 0.7752 0.0888 0.9699 15.4400 0.9703 0.4013
**FB2 0.8763 1.7382 0.7393 0.0702 0.9611 14.4618 0.9600 0.4619
**FB3 0.8942 1.547 0.7905 0.0853 0.9450 10.7767 0.9442 0.3989
Note: *Formulations FH1–FH3 were LPHNPs loaded with DOX.HCl, while **FB1–FB3 were loaded with DOX base.
Abbreviations: DOX, doxorubicin; DOX.HCl, doxorubicin hydrochloride; LPHNPs, lipid polymer hybrid nanoparticles.
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Figure 3 FTIR spectra of PLGA (A), lecithin (B), DSPE-PEG 2000 (C), Luterol (D), DOX (E) blank formulation (F), and DOX loaded LPHNPS (G).
Abbreviations: DOX, doxorubicin; DSPE-PEG 2000, 1,2-distearoyl-Sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)]-2000; LPHNPs, lipid polymer
hybrid nanoparticles; PLGA, poly (D, L-lactide-co-glicolide).
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uptake.39 Different combinations of the structural com-
ponents and drug might exist, like the amorphous drug
and the crystalline structure of the polymer. Figure 4
shows the thermograms of pure DOX, PLGA, lecithin,
physical mixture, and drug loaded LPHNPs. A PLGA
thermogram (Figure 4A) shows a characteristic peak at
50°C that correlates with the glass transition temperature
of the polymer and is not affected by the formulation
procedure.40,41 A DSC thermogram of DOX presents
a typical endothermic melting peak ca 220°C, demon-
strating the crystallinity present in the DOX molecular
structure (Figure 4E). However, a broad and slightly
shifted peak was observed in the physical mixture
(Figure 4D), and no such peak was identiﬁed in the
DSC thermogram of the LPHNPs (Figure 4G), indicating
that either the drug is completely loaded inside the core
material or loses its crystalline structure due to structural
deformations.42 The results indicated the change of the
physical state of the drug during the NPs
formulation.43,44 It is suggested that the conversion
from crystalline to amorphous phase increases the drug
saturation solubility and inhibits the Ostwald ripening
phenomenon.45 It was also revealed from the data that
there was no signiﬁcant change in the characteristic peaks
of all the structural components in the LPHNPS thermo-
grams, conﬁrming the compatibility among the drug and
formulation components. Thus, all these factors suggest
that these LPHNPs formulations show better stability and
in vivo performance.46
Colloidal stability of LPHNPs
The colloidal stability of the fabricated LPHNPs was
explored in PBS, DMEM, and RPMI, which is an indica-
tion of biocompatibility and safety after in vivo use of
these LPHNPs. The ﬁndings of particle size, PDI, and
zeta-potential revealed good stability (Figure 5). LPHNPs
showed slightly larger sized particles in DMEM and RPMI
media that might be due to the interaction between the NPs
and the proteins present in the growth media. The nega-
tively charged surface of LPHNPs offered excellent phy-
sical stability to these nanocarriers that is an indication of
their suitability for further evaluation.16,29
Cell viability studies
The investigation of the toxicity proﬁle of the drug deliv-
ery system is of prime importance in the translation for
biomedical applications.19 The biocompatibility and viabi-
lity were evaluated in MDA-MB-231 and PC3 cells at
various concentrations (up to 300 µg/mL) of the
LPHNPs and exposure time. The main aim of using var-
ious concentrations was to evaluate the dose or concentra-
tion dependent toxicity and the maximum safe
concentration of LPHNPs that might be administered for
50
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F
G
100
Temperature (°C)
150 200 250
Figure 4 DSC thermograms of PLGA (A), lecithin (B), DSPE-PEG 2000 (C), physical mixture (D), DOX (E), blank LPHNPs (F) and DOX loaded LPHNPS (G).
Abbreviations: DOX, doxorubicin; DSC, differential scanning calorimetry; DSPE-PEG 2000, 1,2-distearoyl-Sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene
glycol)]-2000; LPHNPs, lipid polymer hybrid nanoparticles; PLGA, poly (D, L-lactide-co-glicolide).
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the clinical application of these NPs. The particles were
evaluated for two different incubations periods, 24 and 48
hours, and the results are shown in Figures 6 and 7. After
the selected time period no cytotoxicity was observed, as
the viability of both type of cells was approximately 100%
at all tested doses, being similar to the control sample.
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Figure 5 Colloidal stability studies, indicating the variation in particle size (A), PDI (B), and zeta-potential (C) in PBS, DMEM, and RPMI up to 4 hours at 37°C. All the
results are presented in triplicate, along with error bars, as mean±SD (n=3).
Abbreviations: DMEM, Dulbecco’s Modiﬁed Eagle Medium; PBS, phosphate buffered saline; PDI, polydispersity; RPMI, Rosewell Park Memorial Institute.
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Figure 6 Cell viability study of the blank LPHNPs after 24 hours (A) and 48 hours (B) incubation with MDA-MB-231 cells at 37°C. The results are presented in triplicate
with error bars as mean±SD (n=3).
Abbreviation: LPHNPs, lipid polymer hybrid nanoparticles.
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Figure 7 Cytotoxicity study of LPHNPs measured after 24 hours (A) and 48 hours (B) incubation with PC3 cells at 37°C. The results are presented in triplicate, with error
bars as mean±SD (n=3).
Abbreviation: LPHNPs, lipid polymer hybrid nanoparticles.
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Similarly, no signiﬁcant cell death was observed
after 48 hours, even at the highest concentration (300
µg/mL) of the LPHNPs. Our ﬁndings are supported by
various studies conﬁrming the safe nature of the
LPHNPs and elaborating no signiﬁcant toxic
effects.47–49
Cell uptake study
The extent of cellular internalization of the NPs and the
intracellular drug release are two main indicators of the
drug delivery potential of a nanocarrier system. DOX
hydrochloride and DOX base loaded LPHNPs were incu-
bated (at a concentration of 25 µg/mL of the DOX in the
LPHNPs and the free drug solution) with cancer cells,
and the internalization of NPs was investigated using
confocal ﬂuorescence imaging at 37°C. Due to the
ﬂuorescent nature of the DOX itself, no other ﬂuores-
cence dye was loaded into the NPs; however, for the
ﬂuorescence imaging, the cells were stained with DAPI
and CellMask Deep Red to identify the nuclei and cell
membranes, respectively (Figure 8). The LPHNPs
showed a dose and time dependent cell internalization
through the cell membranes that might follow the endo-
cytosis pathway. Initially, the ﬂuorescence signals of the
drug inside the cell were relatively weak as compared to
the signals at higher concentration. It was also found that
the ﬂuorescence signals of the DOX.HCl LPHNPs were
mainly localized at inner and outer compartments of the
cells membrane. Moreover, the intense ﬂuorescence sig-
nals of DOX loaded LPHNPs were observed in the inner
cytoplasmic region, and even early/fast uptake was iden-
tiﬁed in the nuclei. The results suggest that the presence
of lipid coating simulates with cell membranes structure
that would facilitate the uptake of these NPs.50 However,
the NPs loaded with the hydrophilic form of the DOX
had less uptake, which may also be followed by the rapid
efﬂux from the cells due to less permeability and rapid
release from the NPs. The results are further supported by
the previous data that demonstrated that the physical
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Figure 8 Confocal microscopic images of LPHNPs containing DOX solution. DOX.HCl and DOX base growing for 24 hours at 37°C in breast cancer cells. DAPI
(blue) and CellMask Deep Red (red) were used to stain the different components of the cell. Green signals indicate the presence of DOX in the cells.
Abbreviations: DOX, doxorubicin; DOX-HCl, doxorubicin hydrochloride; LPHNPs, lipid polymer hybrid nanoparticles.
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binding of DOX with cell membrane lipids produced
higher cellular internalization and retention inside the
cellular compartments.51,52 The loading of DOX.HCl
and the DOX into the polymersomes by Xu et al21 also
support our ﬁnding by describing the effect of hydrophi-
licity and hydrophobicity on the cytotoxic effects and cell
permeation in the MCF-7 cells and demonstrated the
higher uptake of the lipophilic DOX. It was also estab-
lished that NPs with particle sizes of ≤200 nm might
improve the cellular uptake and intracellular concentra-
tion of the loaded drug by enhanced permeability and
retention effects that ultimately enhanced the therapeutic
efﬁcacy.53
Antiproliferative assay
The antiproliferative effects of both formulations were
evaluated and compared with the drug solution in MDA-
MB-231 human breast cancer cells and PC3 human pros-
tate cancer cells. The results indicate the concentration
and time dependent antiproliferative effects with pure
DOX solution and LPHNPs, containing the DOX.HCl
and lipophilic DOX base, respectively (Figures 9 and
120
A B
10µg/mL5µg/mL 50µg/mL 100µg/mL20µg/mL 200µg/mL150µg/mL
100
80
60
20
40
0
Co
ntr
ol
DO
X
DO
X
NP
s@
DO
X.
B
NP
s@
DO
X.
B
NP
s@
DO
X.
HC
I
NP
s@
DO
X.
HC
I
Co
ntr
ol
%
 C
el
l v
ia
bi
lit
y
120
100
60
80
40
20
0
%
 C
el
l v
ia
bi
lit
y
ns
ns
ns ns
*
* * ***
*
*
Figure 9 Cell growth inhibitory effects of the DOX solution, DOX.HCl loaded LPHNPs and DOX base loaded LPHNPs measured after 24 hours (A) and 48 hours (B)
incubation along MDA-MB-231 cells. The activity was determined by CellTiter Glo viability assay. Results are presented with error bar, indicating mean±SD (n=3). *Signiﬁcant
where P>0.05, **signiﬁcant where P>0.01.
Abbreviations: DOX, doxorubicin; DOX-HCl, doxorubicin hydrochloride; LPHNPs, lipid polymer hybrid nanoparticles; ns, non-signiﬁcance.
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Figure 10 Cell growth inhibitory effects of the DOX solution, DOX.HCl loaded LPHNPs and DOX base loaded LPHNPs measured after 24 hours (A) and 48 hours (B)
incubation along PC3 cells. The activity was determined by CellTiter Glo viability assay. Results are presented with error bar, indicating mean±SD (n=3).
*Signiﬁcant where P>0.05, **signiﬁcant where P>0.01.
Abbreviations: DOX, doxorubicin; DOX-HCl, doxorubicin hydrochloride; LPHNPs, lipid polymer hybrid nanoparticles; ns, non-signiﬁcance.
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10). The results also indicate the encapsulation of the
DOX inside the LPHNP, which retained its antitumor
activity and was signiﬁcantly higher compared to the
pure drug solution. The higher activity was due to the
greater uptake of the LPHNPs in the cell. The ﬁndings
are supported by previous studies that indicated the incor-
poration of the DOX within the lipid polymer hybrid
system hindered efﬂux and rapid removal of the DOX
from the cells.54,55 Another important ﬁnding is the
higher antiproliferative effect of lipophilic DOX base
compared to the DOX.HCl, due to the hydrophobic inter-
action between LPHNP components and the DOX that
improves the permeability and penetration of the
LPHNPs across the cell membranes.51,56
Conclusions
In this study, we successfully fabricated DOX.HCl and
DOX base loaded LPHNPs by the modiﬁed single step
nanoprecipitation method and evaluated different physico-
chemical properties. The particle size analysis indicated the
LPHNPs with a size range of 174–208 nm have good
dispersity (PDI<0.3). The particles showed higher encapsu-
lation of DOX base (59.8±1.4) compared to DOX.HCl
(43.8±4.4) due to its lipophilic nature. The LPHNPs loaded
with DOX base provide slower drug release (32.9%) as
compared to DOX.HCl after 24 hours. The FTIR and
DSC analysis showed the physicochemical compatible of
the particles and its components. Moreover, the in vitro
viability and cell internalization studies indicated better
safety, enhanced antitumor effect, and cell uptake. These
characteristics may endow LPHNPs improved therapeutic
effects in the tumor microenvironment. Altogether, the
LPHNPs provide a signiﬁcantly important DDS chemother-
apeutic delivery for future anti-cancer applications.
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